Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of rozanolixizumab in persistent or chronic primary immune thrombocytopenia
2019-000883-40Phase 3Terminated
- Sponsor
- UCB
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rozanolixizumab in immune thrombocytopenia (ITP) and Thrombocytopenia, sponsored by UCB. Primary endpoint: Occurrence of treatment-emergent adverse events (TEAEs). Started Aug 2020; status: terminated.
02
Drugs
rozanolixizumab
03
Conditions
immune thrombocytopenia (ITP)Thrombocytopenia
Beyond the preview
Go deeper on 2019-000883-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000883-40.